DexCom (DXCM)
(Delayed Data from NSDQ)
$112.13 USD
+0.48 (0.43%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $112.47 +0.34 (0.30%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DXCM 112.13 +0.48(0.43%)
Will DXCM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DXCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DXCM
CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings
IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates
DXCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
AMN Healthcare (AMN) Unveils ShiftWise Flex Manager Hub App
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
How to Play Intuitive Surgical (ISRG) Ahead of Q2 Earnings?
Other News for DXCM
Dexcom’s Market Leadership and Strategic Growth Opportunities Affirm Buy Rating
Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers
Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.
Have $50K? 7 Stocks to Buy to Retire With $1 Million by 2034
Tandem Diabetes, DexCom see weakness following ADA conference